Podcasts about Phase

LSD shows promise for anxiety treatment. A Phase 2b clinical trial found that 100 micrograms of MM120 (pharmaceutical LSD) reduced anxiety significantly with lasting effects Study results were encouraging. Researchers noted that 65% of participants experienced clinical response at optimal dosing, with 47.5% achieving remission that sustained through 12 weeks of follow-up Safety profile was manageable. Most side effects occurred during dosing sessions and resolved quickly, with visual changes and nausea being most common under medical supervision Note that LSD remains illegal. It is currently classified as Schedule I controlled substance, accessible only through approved clinical trials, with results of Phase 3 trials expected by 2026 In the meantime, natural anxiety alternatives exist. Breathing techniques like nasal breathing, horizontal breathing patterns, and controlled breathing practices can help manage anxiety symptoms without medication

For the second time in 4 weeks, Jim "Smitty" Smith joins Joe for an "off the cuff" podcast conversation! Specific topics discussed include: Behind-the-scenes insight into Phase 2 of Built Different; A nuanced approach to training variability (and programming in 4-week blocks); 3 things that the "happiest people in the world" always have; Valuable gym lessons from high achievers; How to get your weaker limb stronger in record time; Remembering Mike Mentzer; The difference between "science-based coaches" & "science-based KIDS"; How to blow up your biceps in ONE iNsAnE set...And so much more! *For a full list of Show Notes + Timestamps visit www.IndustrialStrengthShow.com. IMPORTANT LINKS Team Forever Strong [FREE Trial] Iron Business Blueprint [Apply Now] Smitty's Instagram Joe D's Instagram Manukora Honey

Carl Rivera is the Chief Design Officer at Shopify, where he previously led both Merchant Services and the Shop App as VP of Product. Before joining Shopify through its acquisition of Tictail, Carl was the co-founder and CEO of Tictail, the "Tumblr for e-commerce," where he built one of the most beloved design-forward commerce platforms of its era. AGENDA: 05:05 Biggest Lessons from Selling My Company to Shopify 09:55 Where Does Shopify Suck at Product: Lessons from that? 17:37 What makes Truly Great product Design: The Five Pillars 31:02 The Future of Design in an AI-Driven World 36:00 Do We Skip the Design Phase in AI: Figma's Evolving Role in Design 40:09 Remote Work vs. In-Person Collaboration: Where Remote Loses? 42:43 What Happens to the Vibe Coding Market 47:06 Product Management and Team Dynamics 59:48 Does AI Favour Incumbents or Startups  

Send us a text if you want to be on the Podcast & explain why!Most new trainers don't fail because they're lazy—they fail because they were set up to memorize, not to coach. We sit down with Cori, a dedicated runner navigating NASM overwhelm, and turn tangled chapters into clear, usable coaching. You'll hear how to translate planes of motion into exercises you can demo immediately, how to spot agonists and antagonists without guessing, and how to use synergists and stabilizers to make your cues land.We walk through the OPT model the way hiring managers want to hear it: Phase 1 builds control and competency, Phase 2 pairs stable with less stable for smarter supersets, Phase 3 drives muscle, Phase 4 loads heavy for strength, and Phase 5 blends power and strength with purpose. You'll get a no-fluff take on energy systems and fiber types—anchored to duration and intensity—so exam questions become quick wins. Then we make assessments useful: identify what “arms fall” and “knees cave” really mean, apply the red-versus-green muscle lists, and choose fixes that actually change movement. Foam roll and stretch what's tight, strengthen what's sleepy, and cue breathing and bracing so reps look and feel better.Safety and screening matter, so we hit the essentials: PAR-Q, hypertension basics, the SA node, and knowing when to refer out. More importantly, we show how hands-on learning, live feedback, and mentorship build confidence faster than any textbook—because clients won't ask about amortization, they'll ask for results. If you've been grinding through chapters and still feel stuck, this conversation gives you a study map, coaching language, and a training method you can use tomorrow.If this helped you see the path more clearly, follow the show, share it with a trainer friend, and leave a quick review—it helps more future coaches find their footing.Want to ask us a question? Email email info@showupfitness.com with the subject line PODCAST QUESTION to get your question answered live on the show! Our Instagram: Show Up Fitness CPT TikTok: Show Up Fitness CPT Website: https://www.showupfitness.com/Become a Personal Trainer Book (Amazon): https://www.amazon.com/How-Become-Personal-Trainer-Successful/dp/B08WS992F8NASM / ACE / ISSA study guide: https://www.showupfitness.com/collections/nasm

"All you folks that want $5,000 gold and $10,000 gold — be careful what you wish for. That's not the kind of world you want to live in." — Frank GiustraIn today's interview with Daniela Cambone at the Precious Metals Summit in Zurich, Giustra delivers a masterclass on the seismic shifts reshaping global finance, the explosive run in gold, and the looming battle for monetary supremacy.He argues that the weaponization of the U.S. dollar has fueled an unstoppable de-dollarization trend, paving the way for a China-led “digital superhighway” that could challenge the dollar's global standing. Giustra breaks down why efforts to “dollarize” other economies are a non-starter — and why the real threat to U.S. dominance may be the gold-backed system already taking shape across the Global South.✅ FREE RESOURCESDownload The Private Wealth Playbook — a data-backed guide to strategically acquiring gold and silver for maximum protection, privacy, and performance. Plus, get Daniela Cambone's Top 10 Lessons to safeguard your wealth (FREE)

Mike Maloney: Gold, Silver Bull Run in Final Phase, I Expect "Spectacular" Prices Mike Maloney of ‪@Goldsilver explains why this time really is different for gold and silver, pointing to factors including growing mainstream adoption, and noting that much more of the world's population is able to buy precious metals than in previous cycles. "This is just like a whole new world — this to me signals the beginning of the third and final phase of the bull market — and that is where you have the greatest amount of gains in the shortest period of time. So we should be seeing some fireworks coming," he said.   Watch this video at- https://youtu.be/Yl7B9tFCicY?si=JktrazBIo4z-WbCT Investing News 59.9K subscribers 14,720 views Nov 11, 2025 #Investing #Gold #Silver ❓ Is the gold-silver ratio part of your buying strategy? Tell us in the comments! Read free chapters of Mike's book: https://ggsr21.com/ This interview was filmed on November 3, 2025. #Investing #Gold #Silver 0:00 - Intro 1:20 - This time is really different 4:47 - Final phase of bull market 7:49 - "Giant crisis" in the works 11:21 - Trigger for market crash 13:15 - Farmland offers protection 15:25 - Gold-silver ratio strategy 19:47 - Gold, silver price potential 23:11 - Outro ________________________________________________________________ Investing News Network (INN) Find out more about investing by INN @ https://investingnews.com/ Browse our 2025 outlook reports: http://bit.ly/3JHyR1M Follow us on Facebook:   / investing.news.your.trusted.source   Follow us on Twitter: https://x.com/inn_resource

In this episode, ARK's Cathie Wood and Brett Winton sit down with Sean McClain, Founder and CEO of AbSci, to explore how generative AI is reshaping drug discovery, development timelines, and clinical costs. Sean walks through real-world examples of AI-designed antibodies—such as AbSci's breakthrough HIV antibody and a regenerative treatment for hair loss—and explains how these platforms are helping unlock previously “undruggable” biology.They discuss AbSci's Phase 2-ready hair growth antibody (BS201), the company's partnerships with Caltech and AMD, and why the FDA's evolving embrace of AI could accelerate the end of animal testing. The conversation closes with a forward-looking discussion on the role of regenerative medicine in longevity—and why AI drug discovery might just pull biotech out of its multi-year bear market.Key Points From This Episode:(00:00:00) How AbSci uses generative AI to design antibodies from scratch(00:02:42) HIV, ion channels, and the promise of targeting "undruggable" biology(00:06:28) AbSci's BS201 drug for hair regrowth: mechanism, speed, and cost advantages(00:13:20) Clinical timeline: From concept to Phase 2 readout in 3.5 years(00:15:34) Bringing costs down: $100–150M vs. the industry average of $2.4B(00:17:36) Why AI enables “keys designed for specific locks” in drug targeting(00:22:58) What AbSci's models are trained on—and how prompts work in drug inference(00:25:32) The future of clinical testing: AI replacing animal models(00:36:43) Sarcopenia, strength loss, and regenerative approaches to aging(00:48:10) BS201 as a long-acting pulse therapy—and how it compares to transplants

In the second part of this two-part series, Dr. Bradley Ong explains the four clinical phases of a typical migraine attack.  Show citation:  Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

Explore expert tips for post-operative ACL rehab, including avoiding pitfalls like lacking extension & recommended biofeedback units. Q: What is your favorite phase of post-operative care for ACL repair? A: Phase 2 is a favorite because the athlete is getting off the table, which is exciting both mentally and physically. During this phase, significant gains are made, and progress continues toward returning to running. Q: What is your biggest tip to avoid pitfalls, such as lacking extension, in post-operative care? A: Consistently checking and actively feeling for extension daily is crucial. Make it a habit and an integrated part of the treatment flow to catch any issues early. Even a little bit of load when athletes start doing more of their daily activities can affect extension, so early detection is key. Q: Is lacking extension from one treatment to the next a red flag? A: It is not necessarily a red flag, but it should definitely be noted. This observation prompts consideration of what might have changed between sessions that could have caused the lack of extension. For example, it might indicate that too much activity was introduced. Q: Should fibular head mobilizations be immediately used for lacking extension? A: No, one should not immediately jump to using fibular head mobilizations. However, they can be a successful intervention in certain cases. Q: Can this ACL rehabilitation program be used for other surgeries? A: The framework of this ACL rehabilitation program can definitely serve as a guide for other knee surgeries. However, modifications are necessary based on the specific structures that have been surgically altered. For example, a meniscus repair would require avoiding weight-bearing, unlike an isolated ACL reconstruction. Q: What biofeedback units do you recommend? A: I recommend Mtrigger. It's an app-based unit with an easy setup, and it can be used more functionally beyond just table exercises. Additionally, it is versatile and can be applied in various other post-operative cases.

In part one of this two-part series, Dr. Bradley Ong discusses the prodrome phase of migraine and how it represents the earliest stage of the attack.  Show citation:  Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

Bei Gesprächen über die Gaza-Friedenspläne in Jerusalem haben US-Sonderberater Jared Kushner und Israels Regierungschef Benjamin Netanjahu sowohl über die derzeitige erste Phase, als auch über die nächste Phase beraten.

Kingfisher Metals reported additional drill and soil results from its 2025 program at the HWY 37 Project in British Columbia's Golden Triangle. Nevada King Gold Corp. reported final results from ten remaining holes of its Phase III drill program at the Silver Park East (SPE) target. Collective Mining announced that drilling is now fully underway at the high-grade, tungsten-rich zones of its **Apollo system**. Great Pacific Gold announced Phase 1 diamond drill results from the Sinivit target at its flagship Wild Dog Project in Papua New Guinea. First Mining Gold announced additional 2025 exploration results from the Miroir target at its Duparquet Gold Project in Quebec's Abitibi region. Foran Mining announced H2 2025 exploration results from the Tesla Zone at its McIlvenna Bay Project in Saskatchewan.This episode of Mining Stock Daily is brought to you by… Integra ResourcesIntegra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.comThe Mining Stock Daily morning briefing is produced by Clear Commodity Network. It is distributed throughout the world through your podcast network of choice, and by our friends at the Junior Mining Network. The information presented should not be considered investment advice. Mining stock daily and its affiliates are not responsible for any loss arising from any investment decision in connection with the material presented herein. Please do your own research or speak with a licensed financial representative before making any investment decisions.

Have you ever been in a relationship where your partner starts to feel less romantic, more platonic, or even like your flatmate? You might have experienced roommate syndrome. In this episode with special cohost Jordan Barr, we work out the telltale the signs of a roomie phase, unpack the reasons why it happens and debate whether we should be reframing our expectations of long term relationships.SHOW NOTES:How to get the spark back in your relationship:  https://www.abc.net.au/triplej/programs/the-hook-up/how-to-get-intimacy-back-in-your-relationship-emotional-spark/104535358Has social media cooked our expectations of dating? https://www.youtube.com/watch?v=rilv_GuNQD4Should your partner be your best friend?https://www.abc.net.au/triplej/programs/the-hook-up/should-your-partner-be-best-friend-soulmate-relationship/104132010DM us your thoughts, questions, topics, or to just vent at @triplejthehookup on IG or email us: thehookup@abc.net.auThe Hook Up is an ABC podcast, produced by triple j. It is recorded on the lands of the Wurundjeri people of the Kulin nation. We pay our respects to elders past and present. We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the land where we live, work, and learn.

Have you ever been in a relationship where your partner starts to feel less romantic, more platonic, or even like your flatmate? You might have experienced roommate syndrome. In this episode with special cohost Jordan Barr, we work out the telltale the signs of a roomie phase, unpack the reasons why it happens and debate whether we should be reframing our expectations of long term relationships.

This final lesson covers Phase 3—"the talk"—the structured, honest conversation where you clearly state your non-monogamous terms after the 3–5 month implicit phase. You'll learn the right timing, setting, and messaging (the "Disney sandwich") to maximize acceptance, manage reactions without drama, and negotiate clear boundaries for a sustainable long-term arrangement.

Diese Meditation hilft dir, zur Ruhe zu kommen und wieder klarer zu spüren, was dir wichtig ist. Zunächst wirst du sanft angeleitet, bei dir selbst anzukommen – danach folgt eine etwa zehnminütige Phase in Stille, in der du einfach nur da sein darfst. Ideal, wenn du dich dir einen Moment für Klarheit, Ruhe und Selbstverbindung wünschst.

In dieser Folge von Frauenstimmen spreche ich mit Sabine Buiten, Sozialberaterin, systemischer Coach und Mentaltrainerin. Sie begleitet Frauen durch eine der emotional herausforderndsten Phasen ihres Lebens – dann, wenn der Kragen platzt und klar wird: So geht es nicht weiter.Sabine nennt sich selbst eine Komplizin für Neuanfänge. Mit Erfahrung, Wärme und Humor spricht sie darüber, wie Frauen den Mut finden, sich aus einengenden Lebenssituationen zu befreien – ob in Beziehungen, im Beruf oder in alten Mustern. Wir reden über Trennung, Selbstbestimmung und darüber, wie man erkennt, ob es nur eine Phase ist oder tatsächlich Zeit, loszugehen.Ein Gespräch über das Aufbrechen, bevor man zerbricht. Über Angst, die kleiner wird, wenn man sich bewegt. Und über die Kraft, die entsteht, wenn Frauen sich trauen, ihr Leben wieder selbst in die Hand zu nehmen.Mehr zu Sabine Buiten· www.sabinebuiten.com· Link zu Freebies: Tipps für Komplizinnen - Sabine BuitenMehr zu Ildikó von Kürthy:www.ildikovonkuerthy.deIldikó von Kürthy bei Facebook und Instagram(Hör-)Bücher von Ildikó von Kürthy:Eine halbe Ewigkeit (Buch und Hörbuch)Mondscheintarif (Buch und Hörbuch)Morgen kann kommen (Buch und Hörbuch)Es wird Zeit (Buch und Hörbuch)Weitere Bücher und Hörbücher Hosted on Acast. See acast.com/privacy for more information.

Zwischen „Oh je! War das richtig?“ und „Ich bin angekommen!“ liegt eine Phase, in der unruhige Gefühle ganz normal sind. In dieser Episode sortieren Franca und Christian die typischen inneren Zweifel nach großen Entscheidungen. Woran du erkennst, ob es noch Ankommen ist oder schon Kurskorrektur braucht, wie du mit gezielten Fragen echte Daten über dein neues Leben bekommst, wo Red Flags drohen und ab wann Eingewöhnung zur Fehlanpassung wird, erfährst du in dieser Folge. Diese Folge ist für alle, die nach Jobwechsel, Umzug, Trennung oder großen Entscheidungen ein wenig Orientierung suchen. Mehr Tipps und Ressourcen auf www.franca-cerutti.de Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/psychologietogo Du möchtest Werbung in diesem Podcast schalten? Dann erfahre hier mehr über die Werbemöglichkeiten bei Seven.One Audio: https://www.seven.one/portfolio/sevenone-audio

Building your brave career isn't always about leaping, insisting, disrupting. Sometimes it means staying with intention using. This moment to calm your nervous system, build your skills and inner strength, enhance your financial safety and deepen your real life, your hobbies and your interests, and the most important relationships.Building your brave career is sometimes about bravery in the meantime.Listen to this episode for concrete examples of how to use a difficult career phase to build your long-term career without stressing out, burning out, or limiting your goals. More Links:Check out my websiteJoin my mailing list for more insights, opportunities, and inspirationConnection with me on LinkedInDetailed TranscriptRight now, most women in tech are in a career phase that isn't quite what they expected. I mean, sure some of my clients and some fellow women in tech are moving abroad. Accepting promotions or lowering their stress by working fewer hours, traveling less, taking on less emotional labor. Yes, that is true.What is also true is that most of my clients, and many women in tech, are in a career phase that kind of sucks. They've been laid off with no warning, passed over for deserved, and sometimes even promised promotion, or they're stuck working with people they don't respect on products that aren't quality at companies that don't seem to care. They're watching executives and shareholders, and investors take far more than they could ever create.Because here's a brave truth: it's rough out there for a lot of women in tech, quite frankly, for a lot of everyone. And maybe that's you, and if it is, keep listening.By the end of this episode, you'll have a few ways to build the skill of bravery in your meantime. Even if you're in a job, that kind of sucks. Right now, you may be feeling ignored, stressed, lost, angry, stuck. You may feel held down by bad management and tough, real economic realities, but you're still showing up for work.Maybe you're biting back your sarcasm, your boredom, maybe even your hope. You are watching the cost of everything rise: food, clothing, housing, schooling, everything. It feels threatening. You're saving, but it never feels like enough. And you know that guy who does less and does it poorly is still earning more than you.You want to grow, be bold, create your next career phase, but you've also survived three layoffs in two years. Your friends are struggling, your mentors are struggling. You look around and it feels like just about everyone is struggling.You keep wondering what's right for me right now? Is there anywhere safe anymore?  In the tech industry, we often celebrate the bravery of quitting, founding, leaping, reinventing. We talk about moving fast and breaking things, but sometimes the bravest thing, the best Next thing is choosing to stay. Choosing to stay at a job, that kind of sucks because it gives you the stability you need this month and the next.It helps you rest, build skills, activate your network, and deepen your personal relationships. Yeah, it kind of sucks and you can use this phase.You can use this phase to be your phase of bravery. In the meantime, crafting the foundation you need for that next clear leap. That might be exactly the type of bravery you need right now.Now, before I go any further, I wanna be really clear the rest of this episode is not for you. Or anyone. If you are in a truly unsafe environment, if you're being abused, bullied, harassed, or just frankly not paid, these tips are not for your situation. You need to protect yourself, and you need to seek support.What I'm about to share is for women in tech who are stressed, overworked, underpaid, and trying to stay afloat and craft a future in a very tough season.Today we're talking about how staying, how choosing bravery in the meantime can support your next career and life phase. None of what I'm about to say will help a toxic or abusive situation. Okay?If work feels draining. And it's impacting your life. This is your time to focus on bravery. In the meantime, it's about making conscious choices to build the habits and the skills you need for lowering your stress, for managing your time better. For most of you, that means working less. And setting yourself up in the future for greater income.Because you have built, expanded your sense of self, you've made yourself more valuable on the market. These are tiny habits that remind you of who you are, what you want, and why you matter.This might mean staying quieter in meetings, doing the minimum necessary for success in your role.Pay attention to what I just said : you're still going to meet success for your role. You're going to achieve. Not gonna overachieve you are not gonna extremely achieve. You're going to achieve and do the minimum necessary for achievement in your role.Maybe this means you're gonna be asking fewer questions and listening even more carefully to what is not being said.You're gonna be tracking your time more consciously.You are gonna be showing up on time with an attitude of your choice, and you're also going to be leaving on time in the attitude of your choice.One of my clients who's in a unhelpful boss situation, has chosen her quiet tiny habit, is creating sticky notes and placing them around her apartment. These sticky notes translated into English. Say, " You are an expert. This is a phase I believe in me."She's using these little habits, these little mindset choices as a reminder to keep learning her skills. She's an expert. Even if she has an unhelpful boss, she can still gain and deepen skills.Building her network : this is a phase. It's a phase in her career. The next phase is coming because she's creating it because she believes in herself. Remember her quote, I believe in me . So she's going to events, expanding her network, and she picked up her favorite hobby again.Another client to give you another example, is currently working with three colleagues who consistently drop the ball and then even worse lie about it.Yes, she's keeping a running track of all the times that she saves their butt and all of the lies that they've made. However, what she's focusing on is her phone background is a thank you message from a long-term customer. Every single time she unlocks her phone, she remembers who she's really working for : her craft, her standards, and her future.,Right now she needs to work in this environment, with this healthcare, because she has a child with a disability. But in a few years, she's gonna be going out on her own.She's building the reputation and the skills and the network to set herself up for that success. She's choosing bravery in the meantime. You too. If you are in this type of situation, you need to find your own quiet way to build your brave while you bravely stay.Pick up a hobby you loved as a kid to build your energy and your personal relationship and your belief in yourself. Learn to play the piano again, like one of my clients, or join a hiking group or volunteer locally.Listen, regardless of the phase you're in, keep it simple.I love to say, I read fast and I run slow. I volunteer my time and my heart, and right now I am so privileged, so I'm donating more money than I ever have to feed my neighbors.When you invest time in the parts of your life while you're building these tiny little habits, these quiet moments of bravery in the meantime, you are strengthening your internal safety net.You're sendin...

Listener feedback on non-culprit PCI in STEMI, a major cardiac result in patients on hemodialysis, news on GLP-1 agonists, a dubious stroke trial, and an AHA preview are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Meta-analysis of MI as a surrogate https://pubmed.ncbi.nlm.nih.gov/34694318/ Compare Acute Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1701067 DANAMI-3–PRIMULTI 10.1016/S0140-6736(15)60648-1 External Link CULPRIT-SHOCK https://www.nejm.org/doi/full/10.1056/NEJMoa1710261   II  Huge Cardiac News for Patients with ESRD PISCES article EMBARGOED Till 1130 AM EST PISCES Trial www.nejm.org/doi/full/10.1056/NEJMoa2513032 REDUCE-IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1812792 STRENGTH Trial https://jamanetwork.com/journals/jama/fullarticle/2773120 FISH trial https://jamanetwork.com/journals/jama/fullarticle/1150094 III Obesity Agents White House announces deal with Lilly and Novo on GLP-1 drugs https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/ Amylin Agonists Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf Eloralintide Phase 2 Study https://doi.org/10.1016/S0140-6736(25)02155-5 GLP-1 Comparisons SURMOUNT-5 Trial https://www.nejm.org/doi/10.1056/NEJMoa2416394 Tirzepatide vs Semaglutide in 10-year CVD Risk Reduction https://doi.org/10.1093/ehjopen/oeaf117 IV A Problematic Trial in Stroke Care LAMP trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2840370 V AHA Preview AHA 2025: Mandrola's Four Trials to Look For https://www.medscape.com/viewarticle/aha-2025-mandrolas-four-trials-look-2025a1000u80 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Show Features: Internet Is Undefeated, Blooper Reel and VoicemailsSocials: @DaveandMahoney Voice Mail: 833-Yo-Dummy https://www.twitch.tv/daveandmahoney Additional Content: daveandmahoney.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Are you wayy too competitive? We laugh so hard talking about our embarrassing phases! Are you a part of a social media group? Snitches get tickets .. Morgan Wallen tickets! We end the show playing the list! See omnystudio.com/listener for privacy information.

Are you wayy too competitive? We laugh so hard talking about our embarrassing phases! Are you a part of a social media group? Snitches get tickets .. Morgan Wallen tickets! We end the show playing the list! See omnystudio.com/listener for privacy information.

Ever had a brilliant idea that never made it past your brain? Or watched a dream die because someone poked too many holes in it before you even had a chance to build it?In this episode of Ambitious, George Bryant is back to teach one of the most powerful frameworks I've ever learned. This is the Dream Storming model, originally created by Walt Disney to bring Disneyland to life. We're breaking down the three core buckets (Dreamer, Builder, and Protector), the exact rules for each state, and how to recognize which bucket you naturally live in versus which one you go to when triggered.But here's where it gets really good: this framework isn't just for your business. George and I get vulnerable about how we use this in our long-distance relationship, how it's transformed the way we communicate during conflict, and why understanding someone's dominant state can completely shift the dynamic in your partnerships, friendships, and even with your kids.00:00 Introduction12:25 The Walt Disney Dream Storming Story18:09 Applying the Dream Storming Model33:50 Understanding the Dreamer Bucket34:32 Transitioning to the Builder Bucket35:04 Entering the Protector Bucket35:22 Applying the Dream Storming Process36:02 Facilitating Dream Storming with Teams36:40 The Importance of Discipline in Dream Storming45:41 Interpersonal Applications of Dream Storming50:29 The Power of Divergent Thinking53:31 Recognizing Natural and Triggered States01:05:08 Understanding the Protector Mode01:05:50 Navigating Conversations with Awareness01:12:03 Applying the Framework in Personal and Professional LifeConnect with George: InstagramWebsite  To join the Ambitious Network for free, click HERE. To connect with Kate on Instagram, click ⁠HERE⁠. To apply for ITI, click ⁠HERE⁠.To submit a question to be answered on the podcast, click HERE.

Send us a textIn this episode of WTR Small-Cap Spotlight, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon to discuss the company's mission to transform care for addiction and mental health disorders.Tennyson shares Solvonis' journey from inception to its Phase 3 lead program for alcohol use disorder (AUD), which achieved 86% patient sobriety in prior Phase 2 trials, and details how the company's **dual R&D strategy—repurposing existing molecules and discovering new small molecules—**has allowed it to progress with exceptional capital efficiency. The discussion also covers the SVN-001 and SVN-002 programs, commercialization strategy, and Solvonis' strong financial position and runway through 2027 as it works toward redefining treatment for one of the world's most pervasive unmet medical needs.

Buy Merch Here!  https://otamerch.shop/ Each week we aim to bring together the biggest events in Vtubing and talk about what's been going on. Stop by, hang out, and let's catch up with us! Join this discord : https://discord.gg/M7tVYWTSFR Follow here for updates: https://twitter.com/SuperChatsPod Shorts over here: https://www.tiktok.com/@superchatspod Playlist of music: https://www.youtube.com/playlist?list=PLp6uXoGNUwk9Tq0NWOwaCLGruX0XdVBfd 00:00:00 Intro 00:05:50 New Phase Connect Generation 00:06:45 Wilhelmina 00:11:47 Sinon 00:16:28 Bibi 00:20:13 Nitya 00:23:22 Malice 00:27:06 Hololive on Twitch?! 00:32:49 REM's Sleepover Stage 00:38:08 Maefae Riki Metal 00:38:41 Remilia Redebut 00:40:00 Globie Pride Concert (Soon) 00:40:56 Original Music 00:49:46 Cover Songs 00:54:56 Gigi Birthday Stream 01:02:01 Kam's Gigi Ceci clip 01:03:10 REM Toured Costco 01:04:43 Other Stuff Nick Watched 01:07:36 CC's Octoberfest Bot 01:10:07 Nitya's Lifeline Stream 01:13:58 Saba Dooby Laimu 01:17:00 Mint played Harvester 01:21:23 Ekko and Miwa played Little Nightmares III 01:22:58 Community and Shilling

Dans son discours de jeudi, lors de sa prestation de serment pour un huitième mandat, le président camerounais Paul Biya a appelé ses adversaires politiques à « l'union sacrée », mais a accusé certains politiciens d'être « irresponsables » et a assuré que « l'ordre règnera ». Comment pourrait se matérialiser cette « union sacrée » ? Quelle peut être, à présent, la stratégie de son principal adversaire, Issa Tchiroma ? Armand Leka Essomba enseigne la sociologie à Yaoundé 1 et dirige le Laboratoire camerounais d'études et de recherches sur les sociétés contemporaines. Il est l'invité de Christophe Boisbouvier. RFI : Dans le résultat officiel de la présidentielle, Paul Biya perd quatorze points par rapport à 2018. Est-ce à dire que son parti RDPC traverse un passage à vide ? Armand Leka Essomba : Je pense que cela est évident dans la mesure où on doit pouvoir reconnaître que le parti au pouvoir traverse effectivement une phase de grande perturbation et que probablement soit ce parti, ou alors celui qui l'incarne a perdu probablement une grande part de son attractivité et de son charisme d'antan. Quand l'archevêque de Douala, Mgr Kleda, dit que le résultat officiel de cette présidentielle n'est pas crédible, est-ce qu'il reflète l'opinion de beaucoup de Camerounais ? Disons que ces suspicions, naturellement, sont d'autant plus alimentées que nous sommes à l'ère des réseaux sociaux. Nous avons eu un temps long [entre le jour du vote et le jour des résultats]. La durée des deux semaines, c'est surtout l'injonction qui est faite à tout le monde de ne point communiquer, ni les tendances, etc. Et donc ça jette parfois de la suspicion. La percée d'Issa Tchiroma, même dans les résultats officiels, dans la région du nord et dans les deux régions de l'ouest et du littoral, c'est-à-dire à Douala, quels enseignements vous en tirez ? L'habileté tactique du candidat Issa Tchiroma aura été effectivement d'incarner, à défaut ou par défaut, disons, la synthèse de toutes ces frustrations. Ce d'autant plus qu'un discours social à connotation, j'allais presque dire métaphysique, circulait pour dire qu'il s'agit de transformer cette élection en un référendum pour ou contre Paul Biya. Et finalement, ce qui se révèle, c'est le niveau d'exaspération. Des gens sont prêts tout à fait à dealer avec n'importe qui, à condition qu'ils mettent à la retraite le président dans son exceptionnelle longévité politique. Issa Tchiroma affirme aujourd'hui qu'il y a désormais deux présidents : le président élu, qu'il est lui-même, et le président nommé par le Conseil constitutionnel, c'est-à-dire Paul Biya. Est-ce qu'on va vers un Cameroun coupé en deux ? Ce que je peux dire, c'est d'exprimer quelque peu mon scepticisme. Il est évident que pendant les jours qui viennent, les moments de tension persisteront, notamment dans certaines des régions qui sont des fiefs du candidat Issa Tchiroma. Tout dépendra aussi des mesures importantes qui vont être prises. Donc les mesures d'apaisement, puisque le président de la République, Paul Biya, a demandé à ce qu'une union sacrée se fasse. Il a explicitement fait mention d'une union sacrée. J'ignore si on ira vers des expériences institutionnelles de large ouverture ou d'union nationale, en termes de structuration, par exemple, d'un nouveau gouvernement, mais les jours qui viennent, il faudra être absolument attentif à la manière dont on pourra traduire les propos assez apaisants du chef de l'Etat dans la pratique et dans les orientations politiques. Tout dépendra de ce qui se fera, notamment en termes de gestes d'apaisement, si l'on se réfère au discour d'hier. Et donc l'atmosphère dépendra beaucoup de la traduction politique de cet apaisement. Dans les années 90, Paul Biya avait déjà affronté un adversaire coriace qui proclamait sa victoire et qui organisait des journées ville morte, c'était John Fru Ndi. Et à la fin, c'est Paul Biya qui avait pris le dessus. Est-ce que vous pensez que le même scénario va se reproduire ? Alors personne n'est en mesure de dire ce qui va se passer demain ou après-demain. Mais il est évident que les contextes ont changé. En 1992, Paul Biya était en effet au pouvoir depuis dix ans, il y avait une certaine vitalité humaine et physique. Il faut en tenir compte. La longévité exceptionnelle au pouvoir crée des dynamiques d'inertie systémique et la fragilité physique et humaine, qui est quelque chose de tout à fait naturel, s'associent parfois pour interférer sur, disons la réactivité institutionnelle. S'installent dès lors des formes de paresse, de lenteur, qui peuvent conduire à des expériences d'immobilisme qui sont tout à fait dommageables. Et peut-être dans sa stratégie, Issa Tchiroma compte-t-il sur un essoufflement du parti au pouvoir et de son président ? Alors je crois qu'il y a derrière effectivement un certain imaginaire dans la stratégie d'un certain nombre des challengers de Paul Biya. L'idée que finalement quelque chose pourrait se passer, qu'un accident pourrait survenir et créer les conditions effectivement d'une transition.

Nancy Pelosi gilt als Galionsfigur der demokratischen Partei in den USA. Sie hat angekündigt, nach Ablauf ihrer aktuellen Amtszeit im Januar 2027 zurückzutreten. Über ihre grössten politischen Erfolge – und ob sie jemand in der Partei ersetzen kann. Weitere Themen in dieser Sendung: · Die Situation im Gazastreifen ist festgefahren. Der sogenannte Friedensplan von US-Präsident Trump steckt in der ersten Phase fest und auch die Waffenruhe zwischen der Hamas und Israel ist brüchig. Ein Konfliktforscher aus Deutschland sgat von sich, er wisse, wie man den Konflikt im Gazastreifen entschärfen könnte. · Eine russische Firma lockt vor allem Frauen aus Afrika mit falschen Versprechen nach Russland. Ihnen wird eine Ausbildung und einen guten Lohn versprochen. Kaum in Russland ankommen, entpuppt sich die Realität weniger freundlich: Die Frauen müssen zum Beispiel Drohnen für den Krieg gegen die Ukraine zusammenbauen. · In San Francisco ist eine Katze von einem Auto überfahren worden – von einem Robotaxi. Als das autonome Fahrzeug am Strassenrand gewartet und nach Einsteigen des Gasts wieder losfahren wollte, hatte sich unter dem Rad unterdessen eine Katze gelegt. Sie ist nun tot. Die Robotaxi-Firma drückt dem Besitzer ihr tiefstes Beileid – und schickt Geld.

n einer Phase des europäischen und amerikanischen Kinos, in der sich das System der Studios durchgesetzt hatte und die Filmproduktionen in den riesigen Ateliers, wie wir sie gestern in Babelsberg besuchten, die ganze Welt, zumindest wie man sie sich so vorstellte, nachbauten, war der Film „Die Leuchte Asiens“ des Jahres 1925 eine aufsehenerregende Ausnahme. Dieser Film, der die Lebensgeschichte des Buddha erzählt, war die erste deutsch-indische Koproduktion und wurde weitestgehend in Indien „on location“ mit Laiendarstellern gedreht. Der Film begründete eine lange Zusammenarbeit zwischen dem Regisseur Franz Osten und dem Hauptdarsteller Himansu Rai, für dessen Firma Bombay Talkies Osten bis 1939 unzählige Filme drehte, bevor er, das sei nicht verschwiegen, der NSDAP beitrat. Vom Hamburgischen Correspondenten am 7. November erfahren wir, dass das Passagetheater bei der Hamburger Erstaufführung „indisch“ dekoriert war und es im Foyer eine kleine Ausstellung zum Heimatland Buddhas gab. Die sehr zahlreiche Berichterstattung zu dem Film wimmelt oft von auf Rasselehren basierenden Überlegungen zum Aussehen der indischen Schauspieler*innen und zur Nähe von Europa und Indien. Die entsprechenden Sätze im heutigen Artikel, den Frank Riede liest, stellen eine verhältnismäßig zurückhaltende Variante dieser Überlegungen dar.

We present the eighteenth episode of Eatbrain Radio Season 2, your guide to the dark side of drum and bass! Grimey, dutty and disgusting all the way! Hosted by @5ha5h label// facebook.com/Eatbra1n twitter.com/eatbrain_now instagram.com/eatbrain eatbrain.net Tracklist // 1. Akov & TR Tactics – Reflections [Hanzom Music] 2. Pythius – Inquisition [Blackout Music] 3. Raido & Symplex – Evil Laugh [Eatbrain] 4. Receptor – Punks (Gydra Remix) [Evolution Chamber] 5. Redpill – Bass Infection [Darkshire Sound] 6. Agressor Bunx – Violence [Eatbrain] 7. Tantron & Wiguez feat. Moneo – Alas De Cera [DUB] 8. Osyrus – The Ceremony [Murmuration Records] 9. MNDSCP – We Are Your Friend [Eatbrain] 10. Mefjus & InsideInfo – Mythos [Virus Recordings] (Throwback) 11. Phase & Thread – Need This Shot [Overview Music] 12. Ray Volpe – See You Drop (Audio Remix) [Patreon Exclusive] 13. Burr Oak – Running Next To The Bison (Tesseracts Remix) [Eatbrain] 14. Meph & Karpa – Malice [Darkshire Sound] 15. MV & Deadfussion – The Collaboration [Kosenprod] 16. Mandidextrous & Matt Scratch – Telekinesis [Neuroheadz] 17. Akrom – Phoenix [Skamele Recordings] 18. Ill-Fated – Wicca [Stonx Music] 19. A-Cray – Keep Hiding VIP [Cray Tunes] 20. NOCASE – HARDCORE [Neurotic] (Free Download) 21. Ekwols & HRSPX – The Vigil Abyss [Evolution Chamber] 22. TRCD – The Vortex [VTO Records] 23. Bodrak – Atomic [Paperfunk Recordings] 24. Transforma – Shipwrecked [Warlock Audio] 25. Hoax – Genesis [Hospital Records]

Nach einer kurzen Phase, in der Klimaschutz eine zentrale Rolle in der politischen Debatte einnahm, gerät das Thema wieder ins Hintertreffen. Programme werden gestrichen, Gelder gekürzt. Kann Europa unter diesen Vorzeichen bei der bevorstehenden Weltklimakonferenz im brasilianischen Belém noch Vorreiter sein?Es diskutieren die Europaabgeordneten Lena Schilling (Grüne), Anna Stürgkh (NEOS) und Günther Sidl (SPÖ) mit der Leiterin des FALTER-Naturressorts, Katharina Kropshofer, und Raimund Löw. Hosted on Acast. See acast.com/privacy for more information.

Ever had a brilliant idea that never made it past your brain? Or watched a dream die because someone poked too many holes in it before you even had a chance to build it?In this episode of Ambitious, George Bryant is back to teach one of the most powerful frameworks I've ever learned. This is the Dream Storming model, originally created by Walt Disney to bring Disneyland to life. We're breaking down the three core buckets (Dreamer, Builder, and Protector), the exact rules for each state, and how to recognize which bucket you naturally live in versus which one you go to when triggered.But here's where it gets really good: this framework isn't just for your business. George and I get vulnerable about how we use this in our long-distance relationship, how it's transformed the way we communicate during conflict, and why understanding someone's dominant state can completely shift the dynamic in your partnerships, friendships, and even with your kids.00:00 Introduction12:25 The Walt Disney Dream Storming Story18:09 Applying the Dream Storming Model33:50 Understanding the Dreamer Bucket34:32 Transitioning to the Builder Bucket35:04 Entering the Protector Bucket35:22 Applying the Dream Storming Process36:02 Facilitating Dream Storming with Teams36:40 The Importance of Discipline in Dream Storming45:41 Interpersonal Applications of Dream Storming50:29 The Power of Divergent Thinking53:31 Recognizing Natural and Triggered States01:05:08 Understanding the Protector Mode01:05:50 Navigating Conversations with Awareness01:12:03 Applying the Framework in Personal and Professional LifeConnect with George: InstagramWebsite  To join the Ambitious Network for free, click HERE. To connect with Kate on Instagram, click ⁠HERE⁠. To apply for ITI, click ⁠HERE⁠.To submit a question to be answered on the podcast, click HERE.

Welcome to The Peptide Podcast. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ Before we jump in, I want to quickly address a few comments I have received about the content here. Normally, I wouldn't spend time on something like this, but just for clarity — I have over nine years of formal education, including a Doctorate in Pharmacy, and sixteen years of clinical experience. That includes serving as an adjunct professor at a U.S. pharmacy school and working in oncology and inflammatory disease at a teaching hospital. And yes — for now, you just hear my voice, but that may change. I do plan to incorporate video in the future; I've simply held off because it takes significantly more time to produce, and my priority has been getting the education out to you consistently. Remember, the content is free and meant for education. If it's not for you, that's completely fine — you don't have to listen. It takes a lot of time and energy to put this together, and tuning in is entirely your choice. For my other listeners, thank you for your support and gratitude over the past few years. Now, today we're diving into a compound ATX‑304. It's often referred to as "exercise in a pill". And after we go through the science together you'll see why. We'll cover the back‑story, how it works, how it differs from typical mitochondrial supplements, animal and human data so far, who this may and may not be for — and importantly, what to watch out for.  The Backstory & Why It's Getting Attention ATX-304, was first developed in Sweden by Betagenon AB as a small-molecule AMPK activator designed to mimic the metabolic benefits of exercise and caloric restriction — with the goal of improving obesity, insulin resistance, and overall metabolic health. Early preclinical work in obese and diabetic mice showed impressive results, including better glucose uptake, enhanced fat-burning, improved insulin sensitivity, and even cardiovascular benefits. Human data followed in 2016–2017, where people with type 2 diabetes already on metformin took ATX-304 for about 28 days. Those studies showed reductions in fasting and plasma glucose, improved insulin resistance, and strong safety and tolerability. Today, Betagenon has evolved into Amplifier Therapeutics, and ATX-304 is now in Phase 2 development for metabolic, cardiovascular, and liver-related conditions, with ongoing work to refine oral delivery and broaden its potential uses. What exactly does AMPK do? Think of AMPK as a fuel gauge for your cells. When your cells are running low on energy (like when you haven't eaten, exercised, or your cells are stressed), AMPK turns on. When it's on, it tells the cell to stop storing energy (less fat and cholesterol production), start using energy (burn sugar and fat for fuel), and clean up damaged parts (autophagy, or cellular housekeeping). Basically, AMPK flips the switch from "energy saving" mode to "energy spending" mode, similar to how your body behaves during exercise or fasting. If AMPK is off or underactive, your cells tend to store energy instead of using it, which contributes to weight gain, insulin resistance, and low metabolic activity. So, activating AMPK — like with ATX‑304 — is like giving your body a nudge to burn energy, improve metabolism, and clean up the cells, even without intense exercise. And beyond just turning on AMPK, ATX‑304 also acts as a mild mitochondrial activator, meaning it helps the cell's "power plants" (mitochondria) run more optimally, increasing energy expenditure.  Because of this mechanism, ATX‑304 is sometimes called an "exercise mimetic." Even though it's not a substitute for movement, it triggers many of the same downstream pathways. How It Differs From Mitochondrial "Supplements" There are many supplements out there that claim "boost mitochondria" (e.g., PQQ, CoQ10, NAD precursors). These may support mitochondrial health or function, but typically they don't change the body's energy‑balance set‑point or shift you into a state of enhanced energy usage. ATX‑304, however, directly activates AMPK (the master switch) and supports mitochondrial output — so you get signaling plus hardware improvement. This dual action is what sets ATX‑304 apart.  Also: many mitochondrial supplements lack robust human metabolic‑dysfunction data; ATX‑304 has animal + early human trial data. What About Safety? In human trials (~28 days, T2D patients on metformin) ATX‑304 was safe, well tolerated, lowered fasting plasma glucose and insulin resistance. But because it's still early stage, long‑term safety and outcomes (fat‑loss, muscle preservation beyond short term, cardiovascular endpoints) are not fully proven yet. One of the most exciting things about ATX‑304 is that it encourages the body to burn fat while sparing lean muscle. Because AMPK activation improves muscle glucose uptake and mitochondrial efficiency, your body can preferentially use fat for energy instead of breaking down muscle. Preclinical and early human studies suggest it can reduce fat mass while preserving muscle, which makes it especially interesting for anyone transitioning off GLP‑1 therapies or looking to maintain muscle while losing fat. Practical Dosing in Wellness Context Some peptide clinics use ATX‑304 in doses ranging from 100 to 400 mg a day. It usually comes in 100 mg or 200 mg capsules, and people often take it in the morning to match the body's peak metabolic activity. Cost The last thing I want to discuss is cost. ATX‑304 is currently quite expensive, and there are a few reasons for that. Only a handful of companies manufacture it, so production volumes are small. The synthesis is complex, and the supply chain for key precursors is limited. Since it's still in early development (Phase 2), economies of scale haven't been established yet.  Thanks for listening to The Peptide Podcast.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Until next time, be well, and have a happy, healthy week.  

Inside the day's Moneycontrol Editor's Picks: Danish brewer Carlsberg has picked its advisors for a proposed IPO, PhysicsWallah's founders are set to join the billionaire club, Piramal Finance set to relist on stock exchanges, fiscal second quarter earnings deliver surprise. Also tune in to discover more news from politics to policy, and learn about the latest homegrown AI speech model that has just beaten Google in blind tests.

DEAL: If you're looking for custom socks for your company, event, or sports team, go to hippyfeet.com, fill out the custom inquiry form, and mention the LABEL KING podcast. Michael will give you 15% OFF your first custom order! www.hippyfeet.com

Are you feeling "off" even though you're doing everything "right"? In this solo deep-dive, Coach Debbie maps the North-to-South flow of health—from brain and vagus nerve to stomach acid, bile, liver, gut, and mitochondria—so you can see how fatigue, belly fat, restless sleep, brain fog, and hormone chaos are often communication problems, not willpower problems. You'll learn how to restore safety signals, open drainage, support bile and choline, and retrain mitochondria from defense to performance. We connect the dots with real testing—PNOĒ RMR/AMR, GI-MAP, DUTCH, Total Tox, MRT, genetics, and Nutritional Therapy Analysis—so you can stop guessing and start rebuilding your Future You™. In this episode, you'll learn: The North-to-South Map: why vagal tone, stomach acid, and bile set the stage for metabolism. Mitochondrial intelligence & the Cell Danger Response (OAT and PNOĒ clues you can measure). Drainage before detox: Phase 1–2–3 in plain English—what to do first. Bile & choline: how to make/keep bile flowing (foods, nutrients, signs of stagnation). Cholesterol & bile: why bile is your main cholesterol exit route. The Brain–Bile–Barrier Loop: how gut/BBB permeability drives neuroinflammation. Muscle as metabolic medicine: training & protein targets that signal repair. Testing, Not Guessing: how your data becomes your roadmap. Ready to see what your metabolism is really doing? Book your PNOĒ Metabolic Test + Functional Health Review: www.DebbiePotts.net Resources mentioned: PNOĒ RMR & AMR testing GI-MAP stool test DUTCH hormone panel Total Tox (metals, environmental, mycotoxins) MRT food sensitivity test Genetics + Nutritional Therapy Assessment Who this is for: high-performers in midlife, peri/menopause, athletes and go-getters who feel overtrained, under-recovered, or stuck despite clean eating and supplements. Follow & connect: www.DebbiePotts.net | @coachdebbiepotts Share this episode with someone who needs a data-driven path from Metabolic Chaos® → Metabolic Harmony. Educational only. Partner with a qualified practitioner—especially if you're on medications, have gallbladder disease, significant anemia, active IBD, are pregnant, or have complex conditions.

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Download the transcript here

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Listen to the podcast here

Text us a pool question!Swimming Pool Leak Suspection refers to the initial stage of identifying and investigating potential water loss in a swimming pool system when there is reason to believe a leak may exist.In practical terms, it means a pool owner or service technician has observed indicators suggesting abnormal water loss—such as a consistently dropping water level, air bubbles in the return lines, excessive chemical use, soggy areas around the pool, or unexplained increases in water bills—but has not yet confirmed the presence or location of a leak.Leak suspection triggers diagnostic testing, including visual inspections, the bucket test (to distinguish between evaporation and leakage), pressure testing, dye testing, or electronic leak detection. It's essentially the diagnostic hypothesis phase of leak detection—where symptoms point toward a problem, but confirmation requires controlled testing and data verification. Support the showThank you so much for listening! You can find us on social media: Facebook Instagram Tik Tok Email us: talkingpools@gmail.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

Explaining the “Implicit Phase” (months 1–5) of dating multiple women openly, continuing FB or MLTR dynamics while postponing labels and keeping communication clean. You'll learn how to signal non-exclusivity without lying, handle the “What are we?” question gracefully, and use evidence—not proof—to avoid drama and set up a smooth transition to Phase 3.

Manchmal gibt es Tage, an denen sich alles grau anfühlt. Nichts macht so richtig Sinn, die Energie fehlt – und man weiß vielleicht gar nicht so genau, warum. Diese Meditation möchte dir in solchen Momenten eine sanfte Begleitung sein. Sie hilft dir, wieder in Kontakt mit dir selbst zu kommen, die innere Schwere ein bisschen aufzulösen – und dich daran zu erinnern, dass auch diese Phase vorbeigeht.

There are plenty strategies for hunting the rut. But the ones Canyon talks about on this Full Draw Friday are tried and true ways to put your tag on a mature buck this November. He also talks about why the bucks are doing what they're doing, and how that helps you hunt them.Ridge Hunter Products and Merchandise:Ridgehunteroutdoors.comDiscount Code: RHOPOD for 10% off everything in your orderSupport our Partners:For any info on real estate available through Midwest Farm and Land, or anything that RG Outdoors has, contact Rodney Hawkins 618-925-3153.Check out Raks Big Game Supplements for all your mineral and protein needs! Go to Raksmineral.com and use code FULLDRAW for 15% off your entire order!Submit questions or comments to: Ridgehunteroutdoors@gmail.comFind us on Social:YouTube: https://www.youtube.com/channel/UC50IZ_HE2pnMBjRyPpmgvMg Facebook: https://www.facebook.com/RidgeHunterOutdoors Instagram: https://www.instagram.com/ridgehunteroutdoors/ Twitter: https://twitter.com/RidgeHunterOD

John 11:1-7,Now a certain man was ill, Lazarus of Bethany, the village of Mary and her sister Martha. 2 It was Mary who anointed the Lord with ointment and wiped his feet with her hair, whose brother Lazarus was ill. 3 So the sisters sent to him, saying, “Lord, he whom you love is ill.” 4 But when Jesus heard it he said, “This illness does not lead to death. It is for the glory of God, so that the Son of God may be glorified through it.”5 Now Jesus loved Martha and her sister and Lazarus. 6 So, when he heard that Lazarus was ill, he stayed two days longer in the place where he was. 7 Then after this he said to the disciples, “Let us go to Judea again.”With John 10 behind us, we enter now into a new phase of Jesus' ministry. Phase one opened with John the Baptist baptizing in the wilderness east of the Jordan. That was back in chapter one. Nine chapters later — following a variety of Jesus' miracles and Jesus' teachings, crowds coming and crowds going, Pharisees questioning and Pharisees condemning — we ended up back in the very same place it all began. John 10:40,“Jesus went away again across the Jordan to the place where John had been baptizing at first.” So, phase one has come full circle. Jesus' public ministry has all about concluded. And at this point, life actually looks pretty good for Jesus. John 10:41 says of Jesus, having returned to this region of the Jordan,“And many came to him [so, he's got the crowds]. And many said, “John did no sign, but everything that John said about this man was true [he's got public testimony]. And many believed in him there [he's got ministry success].”Sounds pretty good, right? Jesus is at last away from the tension and death-threats he'd been experiencing in Jerusalem. He's not having to walk mile-after-mile from town-to-town like he did in Galilee. He's east of the Jordan. He's got his disciples all round him. He's got the crowds coming to him and believing him. Life, right now, looks pretty good for Jesus. Then, like a fly in the ointment, John 11 begins,“Now a certain man was ill, Lazarus of Bethany, the village of Mary and her sister Martha.”Hmm, now what might that mean for Jesus? What might that news of one, relatively unimportant person's illness, mean for Jesus — especially in light of crowd-sized, relatively comfortable success? In this morning's text, we're going to see Jesus' response to this one, relatively unimportant person's illness. It's a response that's going to give us a window into three truths about the heart and character of Jesus:Jesus personally loves his people.Jesus prizes his Father's glory.Jesus pursues our very best.Let's pray …. 1. Jesus Personally Loves His PeopleJesus personally loves his people. Let's begin at John 11:1.“Now a certain man was ill, Lazarus of Bethany, the village of Mary and her sister Martha. [and then there's little this parenthesis…] It was Mary who anointed the Lord with ointment and wiped his feet with her hair, whose brother Lazarus was ill.”Now, this is foreshadowing. We've not read about this event just yet, but we will see it in chapter 12. For now, John's just flagging it — saying, “Hey, keep your eye on this family; make note of the connection here: Lazarus, Mary, Martha — they're siblings. Siblings who are going to have some significant interaction with Jesus in the next few days.”So, imagine it with me, Mary and Martha are in their home. Their brother Lazarus gets sick. And sickness is a dangerous thing in the ancient world. Not many options for medicine or doctors. Then, the sickness worsens. Things are beginning to look bad. The sisters think: Let's send for Jesus. Verse 3:“So the sisters sent to him, saying, ‘Lord, he whom you love is ill.'” Again, remember where Jesus was at this time. This message concerning Lazarus gets delivered to Jesus at a time when he's living in relative security. In it comes — the message that Lazarus of Bethany is ill. And, you just gotta think, I mean — “Lazarus, I'm sorry, but the timing's just not great right now. Your location, a bit too close for comfort to Jerusalem. And you're just one person compared to the many who are coming my way.”And, look, let's get real, I mean: how many people had Jesus' interacted with throughout his three years of public ministry? We know he fed the 4,000. We know he fed the 5,000. We know, at times, he had crowds so large he had to get into a boat so as to not be trampled by them. Even now, he's got waves of people coming toward him. You think he even remembers Lazarus? You think he really has capacity — with all the other things he's doing and all the other people he's caring for — to show concern for this one single, relatively unimportant individual?Well, the sisters sure seem to think so. Just look how they describe their brother to Jesus. The message is not, “Lord, he whom you appreciate; he whom you might remember; nor is it even he who loves you. The message from the sisters is, “Lord, he whom you love is ill.”Now, why is it that these sisters believe Jesus loves their brother? Well, I imagine Jesus told them he did. And Jesus showed them he did. That his previous posture toward Lazarus had not been one of cold, detached indifference. Like, when Jesus had been around Lazarus, he had not been checking his watch, or rolling his eyes, or day-dreaming about all the other places he'd rather be. No, no, no, Jesus loved Lazarus and it showed. The sisters knew, Jesus loves our brother. And this, is stunning. Earlier in John — 3:16 — we read that God loves the world. It's an amazing truth, yes? It's also a broad truth — gloriously broad, but broad nonetheless. After all, you've gotta zoom out quite a bit to see the whole world, right? And when you zoom out, what happens to you? What happens to the individual? They fade into the crowd. That is, when humans who are merely humans look at the world. But see, here is where God is different. Here is where Jesus, the Son of God, is different. Jesus has capacity, boundless capacity, to love the world and love individuals within the world. It is not an either/or for Jesus. “Either, I'm a big, distant God. Or, I'm a small, personally involved God.” No, no, no — God loves the world, and God loves his people — collectively, and individually. Calls them by name, counts the number of hairs upon their heads, knows the exact number of days he's given them. Jesus did not love Lazarus generally. Jesus knew Lazarus: Knew what he looked like, knew what he sounded like, knew — even as we'll see in a moment — the details concerning Lazarus' sickness and where it was headed. Jesus knew Lazarus — and his sisters by the way (see that in verse 5) — he knew them personally, and loved them personally. How would you, this morning, describe Jesus' love for you? Do you believe Jesus knows what you look like? What you sound like? What difficulties and sorrows have befallen you? Do you believe that if you, like Lazarus, were to get sick. Get hurt. Need help, and send for Jesus — Do you think Jesus would need a reminder of who you were? Need to jog his memory: “now how exactly is it again that I know this person?” Do you think he'd not be the first to pause the messenger: “wait, wait, wait — I don't need you to describe who she is. I don't need you to tell me who he is. I love that man. I love that woman. And I have since before the foundation of the world.” Look, Jesus' just got done telling us:John 10:14,“I am the good shepherd. I know my own.”John 10:27,“My sheep hear my voice, and I know them.” Jesus, my brothers and sisters, personally loves his people. That's the first truth about Jesus: Jesus personally loves his people. 2. Jesus Prizes His Father's GloryVerse 4:“But when Jesus heard it [that is, heard that Lazarus was sick] he said, ‘This illness does not lead to death. It is for the glory of God, so that the Son of God may be glorified through it.'”Now, we've got to ask: what, exactly, is Jesus getting at here. He says, “This illness does not lead to death.” But, I mean, doesn't it? Lazarus does, in fact, end up dying, right? I mean, he'll be four days in the tomb by the time Jesus finally arrives in Bethany. Four days without a heart beating. Four days without lungs breathing. Four days without any activity in the brain. He dies. And so, when Jesus says, “This illness does not lead to death.” What's he mean? I think there's layers of meaning here, but at the top, is purpose. That is, the purpose of the illness is not death. Yes, his illness will lead to his death, but its purpose is “for the glory of God.”And now, we've seen something like this before in John already. Just two chapters earlier, John 9, the disciples ask Jesus concerning the blind man, “Who sinned, this man or his parents, that he was born blind?” Jesus answered in terms of purpose: “It was not that this man sinned, or his parents, but that the works of God might be displayed in him.”There's purpose to the suffering. Purpose to the plight. That blind man was not blind for nothing. Lazarus is not sick for nothing. The purpose of God is to display the glory of God through the blindness and the illness. So, that's shared ground between John 9 and John 11. Now, what's relatively new here, not only in John 11 but the book of John as a whole, is the complementary dynamic between the Father's glory and the Son's. And, you gotta see this with me. This is an amazing claim being made here by Jesus in verse 4. So, look there with me. Verse 4: Jesus does not just say: “It is for the glory of God.” But, “It is for the glory of God, so that the Son of God may be glorified through it.” The Son is clearly after the Father's glory, yes? And, the way that glory is revealed to the world is through him, through the Son. They are respective, in other words, function in tandem. Jesus magnifies the Father through his obedience to him. The Father magnifies Jesus through his honoring of him. Jesus goes to the cross, it glorifies the Father. The Father raises him from the grave to restore honor to the Son. The Father and the Son's relationship is one of mutual glorification.Now, remember, all of this is under the banner of “Jesus prizes his Father's glory.” Point one: Jesus personally loves his people. Point two: Jesus prizes his Father's Glory. And the fact that the second point follows the first is so important, so helpful, especially in our particular cultural moment. For we live in an age where it is common not just for the world, but for churches, ministries, writers of worship lyrics, to tout a view of Jesus that suggests we are supreme in his mind. We rank highest in his sight. We (and I want to say this as graciously as I can) are almost like God to him. The message is that he needs us, he's incomplete without us, he is unhappy unless we're with him — it's like we're god to Jesus.Now, look, church, Jesus loves us. Point one — he loves you personally. But he does not worship you or me. Jesus loves us, but he does not need us. Jesus loves us, and he's for us, but he's not only for us, as if we are the only thing in all of life that matters to Jesus. Listen, Jesus prizes his Father's glory, and does so supremely. His highest allegiance is not to us, but to his Father. And that is really, really good news, because if that were not true of Jesus, then he'd be a sinner in need of a Savior just like you and me. Jesus prizes his Father's glory, and, he loves us personally.So, Jesus personally loves his people. And Jesus prizes his Father's glory. Finally: Jesus pursues our very best.3. Jesus Pursues Our Very BestVerse 5:“Now Jesus loved Martha and her sister and Lazarus. So, when he heard that Lazarus was ill, he stayed two days longer in the place where he was.”Read that again. When he heard that Lazarus was ill — he'd become aware of the need, aware of Lazarus' suffering, aware of the sisters' anxiety concerning their brother, and then, he stayed two days longer in the place where he was.It's a contradiction, isn't it? Seems it should either read, “Since Jesus hadn't yet heard that Lazarus was ill, he stayed two days longer.” Or, “When he heard that Lazarus was ill, he decided not to stay two days longer, but to race on over to Bethany instead.” But, as it is, the text reads: So, when he heard that Lazarus was ill, he stayed two days longer in the place where he was.” What do we make of this? What's Jesus after? Well, that's precisely the point. What Jesus is after is our very best. See it with me. Watch how this thing unfolds. Verse 7:Then after this he said to the disciples, “Let us go to Judea again. The disciples said to him, “Rabbi, the Jews were just now seeking to stone you, and are you going there again?Simple question, right? Jesus, you mean to go right back to where there's a mob seeking to kill you? It's a simple question. But watch Jesus' answer. Verse 9:“Are there not twelve hours in the day? If anyone walks in the day, he does not stumble, because he sees the light of this world.” Who's the subject of that answer? Jesus had been the subject of the disciples' question, right? “Rabbi, the Jews were just now seeking to stone you, and are you going there again?” Who's the subject of Jesus' answer? Who is it that's walking in the day, seeing the light of the world (not being, but seeing the light of the world), and thereby not stumbling? It's not Jesus. Jesus is the light of the world. Who is it that's seeing the light of the world? It's the disciples. Jesus' answer is about them. Jesus is after what's best for them. And he knows they're frightened by the mob in Judea. Frightened by the danger awaiting them there. And so, he's telling them, “So long as you follow me there, keep me, the light of the world, in front of you, you're not going to stumble.” He's saying, “stay with me. You've got nothing to fear so long as you stay with me.” And now here's the warning. Verse 10:“But if anyone walks in the night, he stumbles, because the light is not in him.”This is the alternative for the disciples. Rather than love the light, and follow Jesus into Judea, they could love the world instead. They could remain in the comfort and safety offered them east of the Jordan. But since Jesus would then be gone, so too would the light. And there, cloaked in darkness, that's when their stumbling would occur. Those are the two options on the table: Light with Jesus as they head into danger. Or comfort without Jesus as they stumble in the dark. And Thomas is the first to get it. Verse 16, skip down there with me for a moment. Verse 16:“So Thomas, called the Twin, said to his fellow disciples, ‘Let us also go, that we may die with him.'”Thomas gets it. He gets it. “Brothers, it is better, better to go with Jesus to our deaths than live here in the dark. Let us go with him, lest we stumble.”Jesus is after our best, brothers and sisters. Not our convenience, not our safety, but our best. And he's willing to delay the miracle, willing to allow Lazarus to die, willing to have sorrow fill the hearts of Mary and Martha. He's willing to bring his disciples away from comfort east of the Jordan. He's willing to lead them right on into the danger of Judea.He's willing to do all this because he does not simply want what's good for Mary, Martha, and his disciples. But he wants what's very best. And what's very best is awaiting them in Judea — waiting for them at the tomb of Lazarus. Verse 14: “Then Jesus told them plainly, Lazarus has died, and for your sake I am glad that I was not there, so that you may believe.” Jesus could have gone to Lazarus sooner. Had he, he would have kept Lazarus from dying. Would've healed him. Would've restored him back to full health. And, oh, how glad that would have made the disciples. How relieved that would have made Lazarus' sisters. But it would have been a gladness and relief with a cost. Their reception of that good gift from Jesus would've meant their missing out on the greatest gift. And Jesus would not have that. Jesus aims to give us what's not merely good, but best — the gift of faith in him. “…for your sake I am glad that I was not there, so that you may believe.” What if suffering was a necessary ingredient for you to maintain your faith in Jesus? Discomfort? Loss and pain? What if, in order to keep you, Jesus needed to delay his help, let the bad news come, allow the tears to fall, and the sorrow to descend, and even stay for days?Could you trust in such a moment:“Jesus is after my best?”“Jesus is giving me what I most need?”“Jesus is taking care of me?”How do we hold onto our trust in Jesus when he's yet to stop the sorrow?We follow him.We follow him from the Jordan, to Bethany, to Judea, to Jerusalem, and up the hill of Golgotha to see him there hanging suffering there for you and for me. Can we trust the man upon the cross? Can we trust the man with scars in his hands? Can we trust the shepherd who lays down his life for the sheep. Jesus died to give us his very best. The TableNow, what leads us to the table this morning, is that death which Jesus willingly went toward, that he might purchase for you and for me a seat at his table. Forgiven by him, washed pure by his blood, restored to fellowship — this table is a foretaste of our future — sitting down at the table of fellowship with Jesus forever.

If you've ever wondered why healing can feel so hard—why it sometimes feels like one step forward and two steps back—you're not alone.For a long time, I thought I could heal by reading enough books, journaling more, or simply “being strong.” I believed that if I just worked hard enough on myself, I could finally move on from the past.But the truth is… you cannot heal alone. None of us can.Healing is not a straight line—it's a journey that unfolds in six essential phases.Each one asks something different of us: courage, surrender, curiosity, community, embodiment, and eventually, reinvention.And when we begin to see where we are in that journey, everything starts to make sense.In this week's episode of Heal Your Relationships, I'm walking you through:What each of these six phases looks likeWhy we get “stuck” in certain stages (and how to move through them)Why true healing requires community and belongingHow to make your healing journey a priority—without suffering through itThese six phases changed the way I see my own past, my relationships, and even my purpose—and I hope they'll do the same for you.Timestamps:0:00 Why healing feels so hard — and why you can't do it alone04:44 Phase 1: The emotionally reactive stage (and the moment that sparks change)07:28 Phase 2: Gathering information — why learning is only the beginning09:46 Phase 3: Finding community and belonging — the real key to lasting change14:04 Phase 4: Embodied healing — when your nervous system finally feels safe15:32 Phase 5: Practicing your true self in real life17:19 Phase 6: Reinvention — living as your healed, whole self19:22 Reflection prompts to help you see where you are in your own healing journeyOh—and if you have something you're navigating and would love my take on it... You can submit a question or situation for a future episode right here (totally anonymous!): Submit your questionP.S. Love the podcast? Reviews help us spread these life-changing tools far and wide. If you leave a 5-star review and submit a screenshot here, I'll send you my Rapid Relationship Repair mini-course—a short but powerful set of tools to reduce conflict and improve connection immediately.FREE tools:Get FREE access to my ‘Conflict Cure' mini-course, plus weekly relationship tools delivered straight to your inbox —> https://bit.ly/RelationalIQ-NewsletterNeed more customized support? Apply for a Relationship Breakthrough Call with Dr. Kavetha Sun —> https://go.oncehub.com/BreakthroughCallwithDrKavethaSun

Tara breaks down the explosive revelations from the Arctic Frost documents, exposing what she calls a “Soviet-style” surveillance campaign against the Republican Party. From Donald Trump's inner circle to every PAC, vendor, and donor, the FBI allegedly monitored phone calls, emails, bank accounts, and digital communications, all under the guise of investigation. Tara walks through the scope of the operation, the key figures involved, and the chilling implications for political freedom and party infrastructure in America. When helping Trump became a felony, no one in the Republican ecosystem was safe. In this episode, Tara examines the scope of the FBI's surveillance operation detailed in the Arctic Frost documents. She explains how every key figure in Donald Trump's 2016 and 2020 campaigns—including managers, PACs, vendors, and donors—was allegedly monitored through bank records, phone calls, emails, and websites. The surveillance reportedly expanded as campaign leadership changed from Brad Parscale to Bill Stepien, encompassing 400+ individuals and 163 organizations. Tara exposes the federal offices and agents she identifies as central to the operation, warns of the ongoing risks these officials pose, and frames the situation as a broader threat to political freedom, privacy, and the integrity of the Republican Party.

   With all the democrat fixation on the Trump Ballroom being built, one democrat stands out above them all and is calling for something so crazy.... we hope it actually happens.  The Ballroom Blitz appears doomed to backfire.      At the same time, pride in America for democrat voters is at a 25 year low.  Sounds like a win to me.    Changes in some of our biggest cities are happening at the top of ICE.  We have the deets on how the Border Patrol will now influence a change in procedure for mass deportations and Phase 2.    Trump scores more deals in Asia as he gets ready to meet with Xi of China.    The Chiefs have one stat this year that stands out above all others.  A new defensive tackle signed by KC is very familiar to all of us.   The Colts new female owner is changing the game on how to run a team... and she's got the top team in the AFC all of the sudden.   KU's Darryn Peterson sits  in an exhibition win, Toronto ties the World Series at two games a piece and our Final Final is a numbers game.

On Wednesday's Mark Levin Show, mass legal and illegal immigration without assimilation causes profound cultural and societal changes, leading to a dark period in Western societies where Marxist-Islamist ideology smothers Enlightenment values. You can see this in NYC where foreign-born voters overwhelmingly support socialist-Islamist immigrant candidate Zohran Mamdani in the mayoral race against Andrew Cuomo and Curtis Sliwa. The Democrat Party relies on Marxist-socialist beliefs for power, abandoning the American founding, Declaration, Constitution, separation of powers, and genuine elections, instead favoring unelected judges, bureaucracy and massive government spending to control the people. Later, Jeffrey Rosen calls in to discuss his new book, The Pursuit of Liberty: How Hamilton vs. Jefferson Ignited the Lasting Battle Over Power in America. Rosen explains the enduring clash between Hamilton's vision of a strong federal government and powerful executive, and Jefferson's emphasis on states' rights and individual liberties.  Also, Phase two of the Gaza peace plan is highly complex involving numerous countries, governments, and figures like Trump, Kushner, Netanyahu, and Dermer, who deserve credit for their efforts. However, Hamas, a terrorist group per its 1988 charter calling for Israel's destruction via jihad, establishment of an Islamic state under Sharia, rejection of negotiations, and anti-Semitic rhetoric, refuses to disarm or surrender, instead centralizing power by torturing and killing challengers among Palestinians. The world, including the UN, universities, and Hamas supporters, remains silent on Hamas's slaughter of fellow Palestinians. Qatar's Emir condemns Israel as committing genocide in Gaza, reaffirms support for Palestine without denouncing Hamas, while Turkey's Erdogan blocks Netanyahu from a regional meeting. Israel previously surrounded and nearly destroyed Hamas but withdrew for peace and international pressure; now, hesitant Arab/Muslim nations refuse troops in Gaza, leaving Israel and the IDF to eliminate Hamas for lasting peace. Learn more about your ad choices. Visit podcastchoices.com/adchoices